Live feed08:30:00·609dPRReleasevia QuantisnowBright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG DataByQuantisnow·Wall Street's wire, on your screen.AIFF· Firefly Neuroscience Inc.DRUG· Bright Minds Biosciences Inc.TechnologyHealth Care
